| pcDNA-dCas9-FLp300 | S.pyogenes dCas9 with c-terminal full length human p300 (aa 2-2414) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of FL human p300 (aa 2-2414) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | Neomycin (select with G418) |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (D1399Y) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutation D1399Y) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (1645/1646 RR/EE) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; mutation 1645/1646 RR/EE) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (C1204R) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; mutation C1204R) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (Y1467F) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inavtivating mutation Y1467F) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (1396/1397 SY/WW) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutation 1396/1397 SY/WW) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (H1415A/E1423A/Y1424A/L1428S/Y1430A/H1434A) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutations H1415A/E1423A/Y1424A/L1428S/Y1430A/H1434A) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pcDNA3.3-Nm-dCas9-p300 Core | Nm-dCas9-p300 Core (Homo sapiens) | CMV | Neomycin (select with G418) |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes N. meningiditis dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664) driven by CMV promoter
pcDNA3.3
EP300 KAT3B, MKHK2, RSTS2, p300
|
| pCCL-PGK-SPdCas9-BFP-DNMT3A | dSpCas9-BFP-DNMT3A, catalytic domain of DNMT3A (Synthetic) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to BFP and the human DNMT3A catalytic domain
3rd Generation lentiviral vector
|
| pCCL-PGK-SPdCas9-BFP-DNMT3B | dSpCas9-BFP-DNMT3B, catalytic domain of DNMT3B (Synthetic) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to BFP and the human DNMT3B catalytic domain
3rd Generation lentiviral vector
|
| pCCL-PGK-SPdCas9-BFP-DNMT3A(E752A) | dSpCas9-BFP-DNMT3A(E752A), DNMT3A catalytic domain with inactivation mutation E752A (Synthetic) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to BFP and the human DNMT3A catalytically inactive domain
3rd Generation lentiviral vector
|
| pCCL-PGK-SPdCas9-BFP-DNMT3B(E697A) | dSpCas9-BFP-DNMT3B(E697A), DNMT3B catalytic domain with inactivation mutation E697A (Other) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to BFP and the human DNMT3B catalytically inactive domain
3rd Generation lentiviral vector
|
| pLenti-EF1a-SPdCas9-DNMT3A-2A-Blast | dSpCas9-DNMT3A catalytic domain (Synthetic) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to human DNMT3A catalytic domain
3rd generation lentiviral vector
|
| pLenti-EF1a-SPdCas9-DNMT3B-2A-Blast | dSpCas9-DNMT3B catalytic domain (Synthetic) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to human DNMT3B catalytic domain
3rd generation lentiviral vector
|
| pLenti-EF1a-SPdCas9-DNMT3A(E752A)-2A-Blast | dSpCas9-DNMT3A(E752A) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to the human DNMT3A catalytically inactive domain
3rd generation lentiviral vector
|
| pLenti-EF1a-SPdCas9-DNMT3B(E697A)-2A-Blast | dSpCas9-DNMT3B(E697A), DNMT3B catalytic domain with inactivation mutation E697A (Other) | | |
Luo
| Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
Gigascience. 2018 Mar 1;7(3):1-19. doi: 10.1093/gigascience/giy011.
|
dCas9 fused to the human DNMT3B catalytically inactive domain
3rd Generation lentiviral vector
|
| pdCas9-DNMT3A-EGFP | S. pyogenes dCas9 fused with the catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-EGFP (Homo sapiens) | CBh | |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of human codon-optimized dCas9-DNMT3A fusion with T2A-EGFP for targeted DNA methylation in mammalian cells; cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pdCas9-DNMT3A-PuroR | S. pyogenes dCas9 fused with the catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-PuroR (Homo sapiens) | CBh | |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of human codon-optimized dCas9-DNMT3A fusion with T2A-PuroR for targeted DNA methylation in mammalian cells; cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pdCas9-DNMT3A-PuroR (ANV) | S. pyogenes dCas9 fused with the inactivated (E756A) catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-PuroR (Homo sapiens) | CBh | |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of mutant human codon-optimized dCas9-DNMT3A fusion (inactive catalytic domain of DNMT3A) with T2A-PuroR; cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pdCas9-DNMT3A-EGFP (ANV) | S. pyogenes dCas9 fused with the inactivated (E756A) catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-EGFP (Homo sapiens) | CBh | |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of mutant human codon-optimized dCas9-DNMT3A fusion (inactive catalytic domain of DNMT3A) with T2A-EGFP; cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pdCas9-DNMT3A-PuroR_hNT | Non-targeting sgRNA human (Homo sapiens) | U6 | |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of dCas9-DNMT3A fusion with T2A-PuroR and non-targeting control sgRNA for use in human cells
pdCas9-DNMT3A-PuroR
|
| pdCas9-DNMT3A-PuroR_v2 | S. pyogenes dCas9 fused with the catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-PuroR_v2 (Homo sapiens) | CBh | Puromycin |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of human codon-optimized dCas9-DNMT3A fusion with T2A-PuroR (v2) for targeted DNA methylation in mammalian cells; cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pdCas9-DNMT3A-PuroR (ANV)_v2 | S. pyogenes dCas9 fused with the inactivated (E756A) catalytic domain of human DNMT3A (amino acids P602-V912) and T2A-PuroR (v2) (Homo sapiens) | CBh | Puromycin |
Zoldoš
| Repurposing the CRISPR-Cas9 system for targeted DNA methylation.
Nucleic Acids Res. 2016 Mar 11. pii: gkw159.
|
Expression of mutant human codon-optimized dCas9-DNMT3A fusion (inactive catalytic domain of DNMT3A) with T2A-PuroR (v2); cloning backbone for sgRNA
PX462
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| TetO-dCas9-D3A | DNMT3A CD aa 598-912 (Homo sapiens) | CMV | |
Challen
| Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation.
Biol Open. 2016 May 11. pii: bio.019067. doi: 10.1242/bio.019067.
|
Expresses dead Cas9 (dCas9) fused to DNMT3A catalytic domain (CD) linked to IRES-mCherry under the control of TetOp and a minimal CMV promoter
Addgene # 20321
|
| TetO-dCas9-mD3A | DNMT3A CD aa 598-912 (Homo sapiens) | CMV | |
Challen
| Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation.
Biol Open. 2016 May 11. pii: bio.019067. doi: 10.1242/bio.019067.
|
Expresses dead Cas9 (dCas9) fused to inactive DNMT3A catalytic domain (CD) linked to IRES-mCherry under the control of TetOp and a minimal CMV promoter
Addgene # 20321
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pCMV-dCas9-D3A | DNMT3A CD aa 598-912 (Homo sapiens) | pCMV | |
Challen
| Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation.
Biol Open. 2016 May 11. pii: bio.019067. doi: 10.1242/bio.019067.
|
Expresses dead Cas9 (dCas9) fused to DNMT3A catalytic domain (CD) under the control of the CMV promoter
pCMV
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pCMV-dCas9-mD3A | DNMT3A CD aa 598-912 (Homo sapiens) | pCMV | |
Challen
| Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation.
Biol Open. 2016 May 11. pii: bio.019067. doi: 10.1242/bio.019067.
|
Expresses dead Cas9 (dCas9) fused to inactive DNMT3A catalytic domain (CD) under the control of the CMV promoter
pCMV
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pPlatTET-gRNA2 | dCas9-5xPlat2AflD-P2A-scFvGCN4sfGFPTET1CD | | Neomycin (select with G418) |
Hatada
| Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions.
Nat Biotechnol. 2016 Aug 29. doi: 10.1038/nbt.3658.
|
All in one vector which contains Cas9 peptide array (linker length: 22aa), antibody-sfGFP-TET1CD, and gRNA expression system.
pCAG
|
| pCAG-scFvGCN4sfGFPTET1CD | scFvGCN4sfGFPTET1CD | | Neomycin (select with G418) |
Hatada
| Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions.
Nat Biotechnol. 2016 Aug 29. doi: 10.1038/nbt.3658.
|
Expression vector for antibody-sfGFP-TET1CD.
pCAG
|
| pdCas9-Tet1-CD | dCas9-Tet1-CD and sgRNA scaffold with 2xMS2 binding sites (Synthetic) | U6, CBH | |
Hu
| A CRISPR-based approach for targeted DNA demethylation.
Cell Discov. 2016 May 3;2:16009. doi: 10.1038/celldisc.2016.9. eCollection 2016.
|
To introduce dCas9-fused Tet1-CD and sgRNA2.0 system
pX330
|
| pcDNA3.1-MS2-Tet1-CD | MS2-Tet1-CD (Synthetic) | CMV | Hygromycin |
Hu
| A CRISPR-based approach for targeted DNA demethylation.
Cell Discov. 2016 May 3;2:16009. doi: 10.1038/celldisc.2016.9. eCollection 2016.
|
To introduce MS2 coat protein fused Tet1-CD
pcDNA3.1-hygro(+)
|
| pLV-dCas9-p300-P2A-PuroR | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens), pac from Streptomyces alboniger (Other) | EFS | Puromycin |
Gersbach
| CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Nat Biotechnol. 2017 Apr 3. doi: 10.1038/nbt.3853.
|
Lentiviral Sp dCas9-p300-P2A-PuroR
lentiCRISPR v2
EP300 KAT3B, MKHK2, RSTS2, p300
|
| Fuw-dCas9-Tet1CD | dCas9-Tet1CD (Homo sapiens) | | Zeo marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
Lentiviral construct to express dCas9 fused with the catalytic domain of Tet1
FUW
|
| Fuw-dCas9-Dnmt3a | dCas9-Dnmt3a (Homo sapiens) | | Zeocin ; Resistance marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
Lentiviral construct to express dCas9 fused with Dnmt3a
FUW
|
| Fuw-dCas9-Dnmt3a_IM | dCas9-Dnmt3a_IM (Homo sapiens) | | Zeocin ; Resistance marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
Lentiviral construct to express dCas9 fused with an inactive Dnmt3a catalytic domain (E664A, E756A)
FUW
|
| Fuw-dCas9-Tet1CD_IM | dCas9-Tet1CD_IM (Homo sapiens) | | Zeocin ; Resistance marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
Lentiviral construct to express dCas9 fused with an inactive catalytic domain of Tet1 (H1672Y, D1674A)
FUW
|
| Fuw-dCas9-Dnmt3a-P2A-tagBFP | dCas9-Dnmt3a (Homo sapiens) | | |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
Lentiviral construct to express dCas9 fused with Dnmt3a-P2A-tagBFP
FUW
|
| 138-dCas9-Dnmt3a | dCas9-Dnmt3a (Homo sapiens) | | Neomycin (select with G418) |
Jaenisch
| Editing DNA Methylation in the Mammalian Genome.
Cell. 2016 Sep 22;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
|
PiggyBac transposon system construct with dCas9-Dnmt3a
PiggyBac
|
| pcDNA3.1-dCas9-MQ1(WT)-EGFP | site-specific DNA-methyltransferase SssI | CMV | Neomycin (select with G418) ; EGFP |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pcDNA3.1
|
| pcDNA3.1-dCas9-MQ1(Q147L)-EGFP | site-specific DNA-methyltransferase SssI (Synthetic) | CMV | Neomycin (select with G418) ; EGFP |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pcDNA3.1
|
| pcDNA3.1-dCas9-MQ1(C141S)-EGFP | site-specific DNA-methyltransferase SssI (Synthetic) | CMV | Neomycin (select with G418) ; EGFP |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pcDNA3.1
|
| pcDNA3.1-dCas9-MQ1(S317A)-EGFP | site-specific DNA-methyltransferase SssI (Synthetic) | CMV | Neomycin (select with G418) ; EGFP |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pcDNA3.1
|
| pcDNA3.1-dCas9-dMQ1-EGFP | site-specific DNA-methyltransferase SssI (Synthetic) | CMV | Neomycin (select with G418) ; EGFP |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pcDNA3.1
|
| pLV hUbC-dCas9-MQ1(Q147L)-EGFP | site-specific DNA-methyltransferase SssI (Synthetic) | hUbC | EGFP; Zeo marker is outside the LTRs and will not be packaged into virus. |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pLV hUbC-dCas9-T2A-GFP (#53191)
|
| pLV hUbC-dCas9-dMQ1-EGFG | site-specific DNA-methyltransferase SssI (Synthetic) | hUbC | EGFP; Zeo marker is outside the LTRs and will not be packaged into virus. |
Goodell
| Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein.
Nat Commun. 2017 Jul 11;8:16026. doi: 10.1038/ncomms16026.
|
Targeted CpG methylation
pLV hUbC-dCas9-T2A-GFP (#53191)
|
| pX330a dCas9-LSD1 | dCas9-LSD1 (Other) | CAG | |
Sauka-Spengler
| Genome and epigenome engineering CRISPR toolkit for in vivo modulation of cis-regulatory interactions and gene expression in the chicken embryo.
Development. 2018 Feb 23;145(4). pii: dev.160333. doi: 10.1242/dev.160333.
|
Modified CAG promoter-containing vector for ubiquitous expression of catalytically inactive Cas9 fused to LSD1. For targeted enhancer demethylation in chicken embryos.
x330
|
| pXPR_123 | dCas9 (Other) | EF1a | Blasticidin |
Root
| Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens.
Nat Biotechnol. 2018 Feb;36(2):179-189. doi: 10.1038/nbt.4048. Epub 2017 Dec 18.
|
for CRISPRi, lentiviral expression of dCas9-p300 2A BlastR.
pXPR
Tag
/ Fusion Protein- p300 (C terminal on insert)
|
| dCas9-hHDAC3 | dCAS9-HDAC3 (Homo sapiens) | EF1A | |
Zhou
| Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC.
Nat Commun. 2017 May 12;8:15315. doi: 10.1038/ncomms15315.
|
3rd generation lenti vector encoding dCas9-hHDAC3 (EF1a-NLS-dCas9(N863)-hHDAC3).
Expresses dCas9 fused to human HDAC3.
plenti
HDAC3 HD3, KDAC3, RPD3, RPD3-2
|
| dCas9-FOG1[N+C] | FOG1(aa 1-45) (Homo sapiens) | CMV | Neomycin (select with G418) |
Segal
| dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.
Nucleic Acids Res. 2017 Sep 29;45(17):9901-9916. doi: 10.1093/nar/gkx578.
|
dCas9 fused to two FOG1 peptide [aa 1-45] , one at the N-terminus and one at the C-terminus of dCas9; pCDNA3 vector backbone, mammalian expression
pcDNA3.3-TOPO
ZFPM1 FOG, FOG1, ZC2HC11A, ZNF408, ZNF89A
|
| SUV[SET]-dCas9 | SUVAR39H1 (Homo sapiens) | CMV | Neomycin (select with G418) |
Segal
| dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.
Nucleic Acids Res. 2017 Sep 29;45(17):9901-9916. doi: 10.1093/nar/gkx578.
|
Catalytic domain [SET] of human SUVAR39H1 fused to N-terminus of dCas9; pCDNA3 vector backbone, mammalian expression
pcDNA3.3-TOPO
SUV39H1 H3-K9-HMTase 1, KMT1A, MG44, SUV39H
|
| G9A[SET]-dCas9 | G9A (Homo sapiens) | CMV | Neomycin (select with G418) |
Segal
| dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.
Nucleic Acids Res. 2017 Sep 29;45(17):9901-9916. doi: 10.1093/nar/gkx578.
|
Catalytic domain [SET] of human G9A fused to N-terminus of dCas9; pCDNA3 vector backbone, mammalian expression
pcDNA3.3-TOPO
EHMT2 BAT8, C6orf30, G9A, GAT8, KMT1C, NG36
|
| DNMT3A-dCas9 | DNMT3A (Homo sapiens) | CMV | Neomycin (select with G418) |
Segal
| dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.
Nucleic Acids Res. 2017 Sep 29;45(17):9901-9916. doi: 10.1093/nar/gkx578.
|
DNMT3A fused to N-terminus of dCas9; pCDNA3 vector backbone, mammalian expression
pcDNA3.3-TOPO
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| LLP185 pLVP-dCas9-DNMT3a V2 | dCas9, DNMT3a catalytic domain (Homo sapiens) | | Puromycin |
Lister
| A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Genome Res. 2018 Jun 15. pii: gr.233049.117. doi: 10.1101/gr.233049.117.
|
dCas9 and DNMT WT on C terminus, 4 NLS, driven by pGK promoter, with P2A site and PURO gene, within a lentiviral transfer backbone
pLVP
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| LLP249 pGK-dCas9-DNMT3a V3 | dCas9, DNMT3a catalytic domain (Homo sapiens) | | Puromycin |
Lister
| A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Genome Res. 2018 Jun 15. pii: gr.233049.117. doi: 10.1101/gr.233049.117.
|
dCas9 and DNMT WT driven by pGK promoter and Puromycin driven by EF1a
LLP185 pLVP-dCas9-DNMT3a V2
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| LLP252 pEF1a-NLS-scFvGCN4-DNMT3a | scFvGCN4, sfGFP, GB1, DNMT3a catalytic domain (Homo sapiens) | | |
Lister
| A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Genome Res. 2018 Jun 15. pii: gr.233049.117. doi: 10.1101/gr.233049.117.
|
Single chain variable fragment antibody GCN4 fused to DNMT3a, binds SunTag, with 3xTy1 tag
LLP245 pEF1a-TALE-DNMT3a-Wt
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| LLP340 pEF1a-NLS-scFvGCN4-DNMT3a (mutant) | scFvGCN4, sfGFP, GB1, DNMT3a catalytic mutant (Homo sapiens) | | |
Lister
| A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Genome Res. 2018 Jun 15. pii: gr.233049.117. doi: 10.1101/gr.233049.117.
|
Single chain variable fragment antibody GCN4 fused to DNMT3a catalytic mutant, binds SunTag, with 3xTy1 tag
LLP252 pEF1a-NLS-scFvGCN4-DNMT3a
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| pINDUCER dCas9-TET1CDMut | dCas9-TET1CD Mut (Homo sapiens) | | EGFP |
Huangfu
| TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.
Nat Genet. 2018 Jan;50(1):83-95. doi: 10.1038/s41588-017-0002-y. Epub 2017 Dec 4.
|
The dCas9-TET1CDMut fusion protein is cloned into the pINDUCER lentiviral backbone (Addgene plasmid# 46948). The TET1 catalytic domain is mutated to abolish catalytic function.
pINDUCER21 (ORF-EG)
|
| pINDUCER dCas9-TET1CD | dCas9-TET1CD (Homo sapiens) | | EGFP |
Huangfu
| TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.
Nat Genet. 2018 Jan;50(1):83-95. doi: 10.1038/s41588-017-0002-y. Epub 2017 Dec 4.
|
The dCas9-TET1CD fusion protein is cloned into the pINDUCER lentiviral backbone (Addgene plasmid# 46948).
pINDUCER21 (ORF-EG)
|
| scFv-sfGFP-DNMT3A1 | DNMT3A1 (Homo sapiens) | | |
Goodell
| DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
Genome Biol. 2017 Sep 18;18(1):176. doi: 10.1186/s13059-017-1306-z.
|
The plasmid encodes a single-chain antibody that binds to the GCN4 peptide from the SunTag system, and is fused to a DNA methyltransferase DNMT3A1
pHR
DNMT3A DNMT3A2, M.HsaIIIA, TBRS
|
| PB-CAG-DDdCas9VPP300-T2A-GFP-IRES-Neo | DDdCas9VP192-P300-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192-P300core activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-CAG-DDdCas9VPPH-T2A-GFP-IRES-Neo | DDdCas9VP192-p65-HSF1-P300-T2A-GFP-IRES-Neo (Other) | CAG | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac transposon system construct with constitutive CAG promoter expression of TMP inducible DDdCas9VP192-P300core-p65-HSF1 activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-CAG
|
| PB-tight-DDdCas9VPP300-T2A-GFP-IRES-Neo | DDdCas9VP192-P300-T2A-GFP-IRES-Neo (Other) | TRE-tight | Neomycin (select with G418) |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
PiggyBac construct with doxycyline inducible TRE-tight promoter expression of TMP inducible DDdCas9VP192-P300core activator followed by T2A-EGFP as a reporter and IRES-Neo as selection
PB-tight
|
| pCXLE-dCas9VPPH-T2A-GFP-shP53 | dCas9VPPH-T2A-GFP-shP53 (Other) | CAG | |
Otonkoski
| Human pluripotent reprogramming with CRISPR activators.
Nat Commun. 2018 Jul 6;9(1):2643. doi: 10.1038/s41467-018-05067-x.
|
EBNA episome plasmid for CAG promoter constitutive expression of dCas9-VP192-P300core-p65-HSF1 followed by T2A-GFP as a reporter. Includes p53 shRNA expression cassette.
pCXLE
|
| pCAG-GBP-dCas9-mRFP | dCas9 (Synthetic) | | Blasticidin |
Bultmann
| Site-specific recruitment of epigenetic factors with a modular CRISPR/Cas system.
Nucleus. 2017 May 4;8(3):279-286. doi: 10.1080/19491034.2017.1292194. Epub 2017 Feb 23.
|
Expression construct for dCas9 fused to GFP-binding Protein (N-terminally) and mRFP (C-terminus)
pCAG
|
| dCas-hHDAC3-R265P | dCas9-HDAC3-R265P (Homo sapiens) | EF1A | |
Zhou
| Locus-specific histone deacetylation using a synthetic CRISPR-Cas9-based HDAC.
Nat Commun. 2017 May 12;8:15315. doi: 10.1038/ncomms15315.
|
Expresses dCas9 fused to human HDAC3 with R265P mutation
plenti
HDAC3 HD3, KDAC3, RPD3, RPD3-2
|
| pcDNA-CasE-p300-Flag | EcoCasE-p300 | CMV | |
Gersbach
| Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells.
Nat Biotechnol. 2019 Sep 23. pii: 10.1038/s41587-019-0235-7. doi: 10.1038/s41587-019-0235-7.
|
Encodes E.coli CRISPR Type I-E CasE with N-terminal fusion of E tag epitope and NLS and C-terminal fusion of NLS, human p300 HAT core (aa1048-1664), and Flag tag epitope driven by CMV promoter
pcDNA
|
| Fuw-dCas9-Tet1CD-P2A-BFP | dCas9-Tet1CD-HA-P2A-BFP (Synthetic) | Ubc | Zeo marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.
Cell. 2018 Feb 8. pii: S0092-8674(18)30049-7. doi: 10.1016/j.cell.2018.01.012.
|
Lentiviral vector to express dCas9-Tet1CD-P2A-tagBFP
Fuw
|
| Fuw-dCas9-dead Tet1CD-P2A-BFP | dCas9-dead Tet1CD-HA-P2A-BFP (Synthetic) | Ubc | Zeo marker is outside the LTRs and will not be packaged into virus |
Jaenisch
| Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.
Cell. 2018 Feb 8. pii: S0092-8674(18)30049-7. doi: 10.1016/j.cell.2018.01.012.
|
Lentiviral vector to express dCas9-dead Tet1CD-P2A-tagBFP
Fuw
|
| Pblu-AAVS1-Cas9-p300-M2rtTA-AAVS1 | spCas9-p300 (Homo sapiens) | | |
Rong
| iKA-CRISPR hESCs for inducible and multiplex orthogonal gene knockout and activation.
FEBS Lett. 2018 Jun 5. doi: 10.1002/1873-3468.13127.
|
Donor plasmid with a Cas9-p300 expression cassette, a M2rtTA expression cassette, a T2A-puro selection cassette, and two gRNA recognition sequences at both ends of the whole insertion DNA fragment.
PbluSKP
EP300 KAT3B, MKHK2, RSTS2, p300
|
| dSpyCas9-p300-P2A-CASANOVA | dCas9-p300-P2A-CASANOVA | | |
Niopek
| Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9.
Nat Methods. 2018 Oct 30. pii: 10.1038/s41592-018-0178-9. doi: 10.1038/s41592-018-0178-9.
|
Co-expresses dSpyCas9 fused to the p300 histone acetyltransferase core domain and CASANOVA
pmCherry-N1
|
| pPB-R1R2_EF1adCas9p300_T2A_MS2p65HSF1-IRESbsdpA | dCas9-p300core-T2A-MS2-p65-HSF1 (Homo sapiens) | | Blasticidin |
Wright
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Expresses dCas9-p300 and MS2-p65-HSF1 fusion proteins
pPB-R1R2-EM7NeoPheS
|
| pPB-R1R2_EF1ap300dCas9VP64_T2A_MS2p65HSF1-IRESbsdpA | p300core-dCas9-VP64-T2A-MS2-p65-HSF1 (Homo sapiens) | | Blasticidin |
Wright
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Expresses p300-dCas9-VP64 and MS2-p65-HSF1 fusion proteins
pPB-R1R2-EM7NeoPheS
|
| pPB-R1R2_EF1aVP64dCas9p300_T2A_MS2p65HSF1-IRESbsdpA | VP64-dCas9-p300core-T2A-MS2-p65-HSF1 (Homo sapiens) | | Blasticidin |
Wright
| Pooled extracellular receptor-ligand interaction screening using CRISPR activation.
Genome Biol. 2018 Nov 26;19(1):205. doi: 10.1186/s13059-018-1581-3.
|
Expresses VP64-dCas9-p300 and MS2-p65-HSF1 fusion proteins
pPB-R1R2-EM7NeoPheS
|
| pEG302-SunTag-FWAgRNA-4-22aa-TET1cd | gRNA4_U6_NOS_TET1CD_2xNLS_1xHA__sfGFP_scFv_UBQ10_INSULATOR_UBQ10_dCAS9_1xHA_3xNLS_10xGCN422aa_OCS (Homo sapiens) | | Hygromycin |
Jacobsen
|
pEG302-SunTag-FWAgRNA-4-22aa-TET1cd
(unpublished)
|
SunTag CRISPR cas9 system that targets the TET1 catalytic domain to the FWA promoter
pEG302
|
| pEG302-SunTagng-22aa | NOS_TET1CD_2xNLS_1xHA__sfGFP_scFv_UBQ10_INSULATOR_UBQ10_dCAS9_1xHA_3xNLS_10xGCN422aa_OCS (Homo sapiens) | | Hygromycin |
Jacobsen
|
pEG302-SunTag-FWAgRNA-4-22aa-TET1cd
(unpublished)
|
Encodes a SunTag CRISPR cas9 system that does not contain a guide RNA and therefore, does not target the TET1 catalytic domain to any specific region of the genome
pEG302
|
| Pinducer20-dCas9-SunTag-2A-BFP | dCas9-SunTag-2A-BFP | TRE | Neomycin (select with G418) |
Goodell
| Homeobox oncogene activation by pan-cancer DNA hypermethylation.
Genome Biol. 2018 Aug 10;19(1):108. doi: 10.1186/s13059-018-1492-3.
|
targeted DNA methylation tool
Pinducer 20
|
| IF311: pMAGIC (R4-R3) NLS-Sa dCas9-NLS-LSD1 | Sa-dCas9/LSD1 (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS Sa-dCas9 fused to the LSD1 H3K4me1/2 demethylase for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| IF405: pMAGIC (R4-R3) NLS-Sa dCas9-NLS-p300core | Sa-dCas9/p300core (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS Sa-dCas9 fused to the p300 catalytic core for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| IP803: pMAGIC (R4-R3) NLS-Sa dCas9-NLS-Dnmt3a3L | Sa-dCas9/Dnmt3a-3L (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS Sa-dCas9 fused to the Dnmt3a-3L DNA methyltransferase for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KQ403: pMAGIC (R4-R3) NLS-x dCas9(3.7)-NLS-LSD1 | x-dCas9(3.7)/LSD1 (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLSx-dCas9(3.7) fused to the LSD1 H3K4me1/2 demethylase for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KO001: pMAGIC (R4-R3) NLS-x dCas9(3.7)-NLS-p300core | x-dCas9(3.7)/p300core (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS x-dCas9(3.7) fused to the p300 catalytic core for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KO101: pMAGIC (R4-R3) NLS-x dCas9(3.7)-NLS-Dnmt3a3L | x-dCas9(3.7)/Dnmt3a-3L (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS x-dCas9(3.7) fused to the Dnmt3a-3L DNA methyltransferase for 3 or 4-component MultiSite Gateway Pro assembly.
pDONR221 P4r-P3r
Tags
/ Fusion Proteins- NLS (N terminal on insert)
- NLS (C terminal on insert)
|
| KL202: pMAGIC (R4-R3) NLS-(SrfI/PmeI)-NLS-LSD1 | 2x NLS/LSD1 (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS/LSD1 scaffold enabling addition of dCas9 mutants into pMAGIC. dCas9 can be inserted via unique SrfI/PmeI restriction sites
pDONR221 P4r-P3r
|
| KL301: pMAGIC (R4-R3) NLS-(SrfI/PmeI)-NLS-p300core | 2x NLS/p300core (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS/p300core scaffold enabling addition of dCas9 mutants into pMAGIC. dCas9 can be inserted via unique SrfI/PmeI restriction sites
pDONR221 P4r-P3r
|
| KL401: pMAGIC (R4-R3) NLS-(SrfI/PmeI)-NLS-Dnmt3a3L | 2x NLS/Dnmt3a-3L (open) (Synthetic) | | |
Newgard
| Creation of versatile cloning platforms for transgene expression and dCas9-based epigenome editing.
Nucleic Acids Res. 2018 Dec 27. pii: 5264291. doi: 10.1093/nar/gky1286.
|
pMAGIC R4-R3 entry plasmid, contains 2x NLS/Dnmt3a-3L scaffold enabling addition of dCas9 mutants into pMAGIC. dCas9 can be inserted via unique SrfI/PmeI restriction sites
pDONR221 P4r-P3r
|
| pcDNA-LmoCas6-p300 | LmoCas6-p300 | U6, CMV | |
Gersbach
| Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells.
Nat Biotechnol. 2019 Sep 23. pii: 10.1038/s41587-019-0235-7. doi: 10.1038/s41587-019-0235-7.
|
Encodes L.monocytogenes CRISPR Type I-B Cas6 with N-terminal fusion of Flag epitope and NLS and C-terminal fusion of NLS, human p300 HAT core (aa1048-1664), and Flag tag epitope driven by CMV promoter
pcDNA
|
CRISPR Plasmids: Epigenetics
